SCHEMBL3883594

SCHEMBL3883594

C=CCc1c(F)ccc(N)c1OC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.37
CYP3A4 P08684 3/20 0.37
ALOX15 P16050 2/20 0.37
TP53 P04637 1/20 0.37
TSHR P16473 1/20 0.37
ALOX12 P18054 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
POLB P06746 2/20 0.36
IMPDH2 P12268 1/20 0.36
PPARG P37231 1/20 0.34
PPARD Q03181 1/20 0.34
PPARA Q07869 1/20 0.34
KDM4E B2RXH2 2/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
CCNB2 O95067 1/20 0.33
CDK1 P06493 1/20 0.33
CCNB1 P14635 1/20 0.33
GSK3A P49840 1/20 0.33
GSK3B P49841 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3885787 0.74 ALDH1A1 (0.40) ALDH1A1CYP3A4SMN1; SMN2POLBKDM4E
SCHEMBL6673395 0.73 IMPDH2 (0.44) ALDH1A1IMPDH2
SCHEMBL4638241 0.72 ALOX5 (0.43) ALDH1A1CCNB2CDK1CCNB1GSK3A
SCHEMBL23829848 0.72 ALDH1A1 (0.37) ALDH1A1CYP3A4TSHRSMN1; SMN2POLB
SCHEMBL10751454 0.70 CYP3A4 (0.41) ALDH1A1CYP3A4ALOX15TP53TSHR
SCHEMBL29398924 0.70 ALOX5AP (0.37) ALDH1A1CYP3A4TSHRSMN1; SMN2KDM4E
SCHEMBL1707536 0.70 ALOX5AP (0.37) ALDH1A1CYP3A4TSHRSMN1; SMN2KDM4E
SCHEMBL18657307 0.69 ADRA2A (0.43) ALDH1A1CYP3A4ALOX15TP53TSHR
SCHEMBL845635 0.69 IMPDH2 (0.53) ALDH1A1CYP3A4ALOX15TP53TSHR
SCHEMBL22366678 0.67 HTR2C (0.37) ALDH1A1CYP3A4ALOX15TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8486962-B2 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2013-07-16 US disclosed
EP-1888063-B1 ANTIFUNGAL AGENTS F2G LTD (GB) 2009-01-14 EP disclosed
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus NAT1, CYP1A2, CYP51A1 ALDH1A1 510/4885CYP3A4 108/4885ALOX15 3949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.